E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Atopic dermatitis |
Atopisk dermatitis |
|
E.1.1.1 | Medical condition in easily understood language |
Atopic eczema |
Atopisk eksem |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Physiological processes [G07] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003639 |
E.1.2 | Term | Atopic dermatitis |
E.1.2 | System Organ Class | 100000004858 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10084010 |
E.1.2 | Term | Atopic dermatitis flare |
E.1.2 | System Organ Class | 100000004858 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
We hypothesize: use of oral systemic antibiotic treatment with dicloxacillin (1000 mg x 3 times a day) will decrease the time to AD improvement as well as the amount of S. aureus and its toxins and alter the skin microbiome. Specifically, we aim to investigate the following research questions: • RQ1: Does the addition of systemic dicloxacillin to TCS treatment result in a more rapid and deeper treatment response? • RQ2: Does the addition of systemic dicloxacillin to TCS treatment affect the skin microbiome, the skin barrier and immune response during improvement of AD? • RQ3: Does topical application of S. aureus or SEB increase the severity and rapidity of a flare? • RQ4: Does topical application of S. aureus and SEB alter the skin microbiome, the skin barrier and immune response during a flare of AD? • RQ5: Can changes in protein expression or metabolic pathways explain the modulated mechanisms in the host-microbial cross talk of AD?
|
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
INCLUSION CRITERIA: - Age 18 years or above - European ancestry - AD diagnosis according to Hanifin & Rajka criteria - AD for at least 3 years - AD that is moderate-to-severe defined as an EASI score of ≥ 7 - AD in the sampled location that has an TLSS score of ≥ 5
|
|
E.4 | Principal exclusion criteria |
EXCLUSION CRITERIA: - Current or present systemic immunosuppressant and/or biological treatment for the past 4 weeks - Evidence of other concomitant inflammatory skin conditions (e.g., psoriasis or contact dermatitis) - Evidence of active skin infection that warrants treatment at screening or baseline visit - Systemic or topical antibiotics in the preceding past 4 weeks - Use of disinfectants, bleach and potassium permanganate baths at least 2 weeks before sampling - UV therapy within the last 3 weeks, or pronounced exposure to sunlight in the preceding 2 weeks - History of any condition (e.g. bleeding diathesis) that may predispose the patient to complications associated with the planned skin biopsy procedures - Other clinically significant medical disease that is uncontrolled despite treatment that is likely, in the opinion of the investigator, to impact the patient’s ability to participate in the study or to impact the study pharmacodynamic, or safety assessments - Decreased kidney function (GFR under 60 ml/min) - Tendency to formation of keloid scars - Penicillin or mometasone futurate allergy or intolerance - Pregnancy - Breast feeding - Body weight ≤ 40 kg - AD only located in the face or intimate regions
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is to describe if addition of systemic dicloxacillin treatment (1000 mg x 3 times a day) to topical treatment with mometasone furoate 0.1% cream once daily increases the rapidity and depth of the treatment response measured as The Total Lesion Symptom Scale (TLSS) score improvement. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After all patients have completed the study. |
|
E.5.2 | Secondary end point(s) |
The secondary endpoint is to describe changes in the skin microbiome measured as community composition, host - microbial cross-talk, immune response, and the epidermal barrier disruption during i) treatment with systemic dicloxacillin treatment (1000 mg x 3 times a day) and mometasone furoate 0.1% cream once daily ii) treatment with mometasone furoate 0.1% cream once daily iii) cutaneous application of respectively SEB and S. aureus from the patient’s self, compared to vehicle.
In addition, we will investigate the changes in itch-NRS, sleep-NRS, pain-NRS, TLSS and EASI score during i) treatment with systemic dicloxacillin treatment (1000 mg x 3 times a day) and mometasone furoate 0.1% cream once daily ii) treatment with mometasone furoate 0.1% cream once daily iii) cutaneous application of respectively SEB and S. aureus from the patient’s self, compared to vehicle. Finally, we aim to investigate the effects of treatment on markers of bone resorption and formation including C-terminal telopeptide of type I collagen (CTX), N-terminal propeptide of type 1 procollagen (P1NP) and parathyroid hormone (PTH), because TCS such as mometasone furoate may increase bone resorption as seen in a large epidemiologic study.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After all patients have completed the study and all biopsies, tape strips, swabs and blood samples are analyzed. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS (approximately December 2023) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |